Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from MIRA Pharmaceuticals, Inc. ( (MIRA) ).
On June 30, 2025, MIRA Pharmaceuticals announced promising results from an animal study using SKNY-1, a drug candidate aimed at tackling obesity and nicotine cravings. The study demonstrated significant weight loss, appetite suppression, and reduced nicotine-seeking behavior in a zebrafish model, with improvements in metabolic activity and neurohormonal balance. These findings support the advancement of SKNY-1 toward further studies, positioning it as a potential key asset for MIRA in a market worth over $200 billion.
The most recent analyst rating on (MIRA) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on MIRA Pharmaceuticals, Inc. stock, see the MIRA Stock Forecast page.
More about MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing next-generation oral therapeutics. The company is under a definitive agreement to acquire SKNY Pharmaceuticals, Inc., which aligns with its market focus on addressing obesity and smoking, two significant global health challenges.
Average Trading Volume: 1,240,626
Technical Sentiment Signal: Buy
See more data about MIRA stock on TipRanks’ Stock Analysis page.